Drug Profile
GNS 396
Alternative Names: GNS396Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Genoscience
- Class
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Acute myeloid leukaemia in France (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in France
- 08 Jul 2016 Preclinical trials in Acute myeloid leukaemia in France (unspecified route)